Eli Lilly And Co (NYSE:LLY) SVP Daniel Skovronsky purchased 10,000 shares of the business’s stock in a transaction dated Thursday, June 14th. The shares were acquired at an average price of $86.22 per share, for a total transaction of $862,200.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Eli Lilly And Co traded up $0.63, hitting $86.35, during midday trading on Thursday, according to Marketbeat Ratings. The company had a trading volume of 3,115,100 shares, compared to its average volume of 4,463,948. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.41 and a quick ratio of 1.01. The firm has a market capitalization of $93.20 billion, a price-to-earnings ratio of 20.18, a P/E/G ratio of 1.45 and a beta of 0.29. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $89.09.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.21. The company had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.51 billion. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the business posted $0.98 EPS. sell-side analysts expect that Eli Lilly And Co will post 5.15 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Gradient Investments LLC acquired a new stake in Eli Lilly And Co in the 4th quarter worth $103,000. Avestar Capital LLC acquired a new stake in shares of Eli Lilly And Co during the 4th quarter valued at about $100,000. Stelac Advisory Services LLC acquired a new stake in shares of Eli Lilly And Co during the 1st quarter valued at about $134,000. Silvant Capital Management LLC acquired a new stake in shares of Eli Lilly And Co during the 1st quarter valued at about $150,000. Finally, McKinley Carter Wealth Services Inc. acquired a new stake in shares of Eli Lilly And Co during the 1st quarter valued at about $153,000. Institutional investors own 76.09% of the company’s stock.
LLY has been the topic of a number of recent research reports. Jefferies Financial Group set a $93.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Monday, February 26th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Tuesday, April 3rd. BMO Capital Markets reiterated a “hold” rating and issued a $78.00 target price on shares of Eli Lilly And Co in a report on Thursday, May 10th. ValuEngine downgraded shares of Eli Lilly And Co from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, Credit Suisse Group set a $82.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a report on Tuesday, May 15th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. Eli Lilly And Co presently has an average rating of “Buy” and an average price target of $93.89.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.